Citi raised the firm’s price target on Argenx to $635 from $512 and keeps a Buy rating on the shares. The firm continues to see room for additional share appreciation through the end of 2024, driven by commercial updates on the initial chronic inflammatory demyelinating polyneuropathy and ongoing generalized myasthenia gravis launch for Vyvgart and Phase 2 myositis data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX: